Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Johnson and Johnson
Mallinckrodt
Boehringer Ingelheim
Merck

Last Updated: February 7, 2023

CLINICAL TRIALS PROFILE FOR OSMITROL 15% IN WATER IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Osmitrol 15% In Water In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00293475 ↗ Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Active, not recruiting National Cancer Institute (NCI) Phase 1/Phase 2 2005-10-14 This phase I/II trial studies the side effects of methotrexate, mannitol, rituximab, and carboplatin and to see how well they work in treating patients with primary central nervous system lymphoma. Drugs used in chemotherapy, such as methotrexate and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Giving methotrexate, mannitol, rituximab, and carboplatin together may be an effective treatment for primary central nervous system lymphoma.
NCT00293475 ↗ Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Active, not recruiting Oregon Health and Science University Phase 1/Phase 2 2005-10-14 This phase I/II trial studies the side effects of methotrexate, mannitol, rituximab, and carboplatin and to see how well they work in treating patients with primary central nervous system lymphoma. Drugs used in chemotherapy, such as methotrexate and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Giving methotrexate, mannitol, rituximab, and carboplatin together may be an effective treatment for primary central nervous system lymphoma.
NCT00293475 ↗ Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Active, not recruiting OHSU Knight Cancer Institute Phase 1/Phase 2 2005-10-14 This phase I/II trial studies the side effects of methotrexate, mannitol, rituximab, and carboplatin and to see how well they work in treating patients with primary central nervous system lymphoma. Drugs used in chemotherapy, such as methotrexate and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Giving methotrexate, mannitol, rituximab, and carboplatin together may be an effective treatment for primary central nervous system lymphoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Osmitrol 15% In Water In Plastic Container

Condition Name

Condition Name for Osmitrol 15% In Water In Plastic Container
Intervention Trials
Recurrent Adult Brain Neoplasm 2
Adult Medulloblastoma 1
Childhood Ependymoblastoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Osmitrol 15% In Water In Plastic Container
Intervention Trials
Brain Neoplasms 2
Syndrome 1
Lymphoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Osmitrol 15% In Water In Plastic Container

Trials by Country

Trials by Country for Osmitrol 15% In Water In Plastic Container
Location Trials
United States 9
Australia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Osmitrol 15% In Water In Plastic Container
Location Trials
Minnesota 3
Oregon 3
Massachusetts 2
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Osmitrol 15% In Water In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Osmitrol 15% In Water In Plastic Container
Clinical Trial Phase Trials
Phase 1/Phase 2 4
Phase 1 1
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Osmitrol 15% In Water In Plastic Container
Clinical Trial Phase Trials
Completed 3
Active, not recruiting 2
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Osmitrol 15% In Water In Plastic Container

Sponsor Name

Sponsor Name for Osmitrol 15% In Water In Plastic Container
Sponsor Trials
National Cancer Institute (NCI) 3
Oregon Health and Science University 3
OHSU Knight Cancer Institute 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Osmitrol 15% In Water In Plastic Container
Sponsor Trials
Other 9
NIH 4
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Mallinckrodt
Boehringer Ingelheim
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.